Carpagnano, G. E., Resta, E., Povero, M., Pelaia, C., D’Amato, M., Crimi, N., . . . Barbaro, M. P. F. (2021). Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci Rep.
Stile di citazione ChicagoCarpagnano, Giovanna Elisiana, et al. "Clinical and Economic Consequences of Switching From Omalizumab to Mepolizumab in Uncontrolled Severe Eosinophilic Asthma." Sci Rep 2021.
Citazione MLACarpagnano, Giovanna Elisiana, et al. "Clinical and Economic Consequences of Switching From Omalizumab to Mepolizumab in Uncontrolled Severe Eosinophilic Asthma." Sci Rep 2021.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.